Mr. Schelling has 21 years of commercial strategy and orphan drug development expertise. He is President and Chief Executive Officer of Acer, which he founded in December 2013. Mr. Schelling also founded Censa Pharmaceuticals Inc. in 2015, which was sold to PTC Therapeutics in May 2020. In addition, Mr. Schelling has also served as a director at Cascade Prodrug, Inc. since June 2017. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical Inc., a Nasdaq-listed biotechnology company, from May 2006 to October 2012. He has also held roles at Abgenix, Inc., Cell Therapeutics, Inc., Stanford Research Institute Consulting and Organon. Mr. Schelling earned a B.A. in biology and history from Carroll College.
